Vision problem leads to man’s stage 4 lung cancer diagnosis, new drug extends survival
“A former Ironman triathlete was stunned to learn that his vision problems were actually the first sign of stage 4 lung cancer. Dave Nitsche, 57, was initially given just 12 to 24 months to live – but an experimental drug has helped him surpass that timeframe by several years.”
Defining Maintenance Therapy and Unmet Needs in ES-SCLC
“Extensive-stage small cell lung cancer (ES-SCLC) remains one of oncology’s most formidable challenges: a disease defined by its aggressive biology, near-universal recurrence, and a treatment landscape that is only beginning to diversify.”
Final Perspectives and Key Messages
“Dr. Wistuba emphasizes the critical need for reinforcing RNA testing alongside DNA testing for comprehensive NGS in lung cancer. Future opportunities include exploring RNA testing in liquid biopsy approaches, despite technical difficulties with RNA-free blood analysis.”
Researchers Find Biomarker of Chemotherapy Resistance in Relapsed Lung Cancer
“Key Takeaways: Standard chemotherapy treatment for small cell lung cancer (SCLC) often leads to resistance and eventual relapse. The YAP1 protein emerges in SCLC tumor samples only after chemotherapy treatment, suggesting it contributes to the acquired resistance. YAP1 is a potential biomarker and therapeutic target to overcome chemotherapy resistance.”
Despite breakthroughs, many go without treatment for metastatic lung cancer
“About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.”
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non–Small Cell Lung Cancer
“Conclusion: ctDNA-based MRD stratifies prognosis after curative resection in NSCLC, with MRD negativity indicating limited benefit from treatment in selected patients and ctDNA clearance reflecting improved outcomes. These findings support the clinical utility of MRD-guided adjuvant treatment strategies.”
Safety and Efficacy of Stereotactic Body Radiotherapy for Centrally Located Early-Stage Non-small Cell Lung Cancer
“Conclusions: A dose of 64 Gy delivered in eight fractions through SBRT exerts good local control and low toxicity for centrally located early-stage NSCLC. This hypofractionated regimen seems to be safe and effective for patients who refuse or are unsuitable for surgery and comparable to results achieved with surgery.”
Investigational Drug Demonstrated Anti-Tumor Activity in Lung and Pancreatic Cancer
“A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers. The therapy shrank tumors in some patients and delayed disease progression, marking a potential step forward for cancers with few targeted treatment options.”
Finding Purpose After a Stage 4 ALK-Positive Lung Cancer Diagnosis
“Patients who are newly diagnosed with cancer should try and focus on continuing to live fully rather than becoming consumed by bitterness or fear, according to Logan Terry, who is living with stage 4 ALK-positive non-small cell lung cancer.”
NASA engineer receives an innovative double-lung transplant at Northwestern Medicine to treat terminal lung cancer
“Chicago, IL – May 10, 2026 – A NASA engineer and mother of two is the first known patient from Houston to receive an innovative double-lung transplant to treat terminal lung cancer. Jodi Graf traveled to Northwestern Medicine in Chicago to participate in a clinical trial known as DREAM, where select patients with advanced lung cancers receive double-lung transplants. Northwestern Medicine is currently the only health system in the country offering this cutting-edge approach for patients with advanced lung cancers who have failed all other treatment options.”
Real-World Considerations for EGFR-Mutated NSCLC Treatment
“This expert roundtable features Sid Devarakonda, MD, director of thoracic medical oncology at the Swedish Cancer Institute; Roy Herbst, MD, deputy director at Yale Cancer Center; and Alex Spira, MD, codirector at the Virginia Cancer Specialists Research Institute, as they explore the rapidly evolving landscape of EGFR-mutated NSCLC management across three key clinical themes.”
Sarasota Memorial IDs lung cancers earlier with analytics platform
“In 2025 alone, 75% of lung cancers diagnosed through the health system’s screening and incidental early detection program were identified at Stage I or II – more than double the national average.”
FDA to Review Updated Taletrectinib Data in ROS1-Positive NSCLC
“A Prescription Drug User Fee Act target date of January 4, 2027 has been set for the application. Taletrectinib is a tyrosine kinase inhibitor (TKI) designed to suppress the growth of cancer cells expressing ROS1 fusion genes and mutations. It is currently approved under the brand name Ibtrozi® for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.”
Video:
Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer
“Dr. Ticiana Leal from Emory University’s Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology discussed recognizing and managing Lambert-Eaton myasthenic syndrome (LEMS) in patients with small-cell lung cancer (SCLC). Cancer-associated LEMS affects approximately 3% of patients with SCLC but remains underdiagnosed in up to 90% of cases due to symptom overlap with disease progression or treatment effects in busy oncology settings.”
